Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle
Open Access

Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds

Neha Murad, Kishore K. Pasikanti, Benjamin D. Madej, Amanda Minnich, Juliet M. McComas, Sabrinia Crouch, Joseph W. Polli and Andrew D. Weber
Drug Metabolism and Disposition February 2021, 49 (2) 169-178; DOI: https://doi.org/10.1124/dmd.120.000202
Neha Murad
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kishore K. Pasikanti
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kishore K. Pasikanti
Benjamin D. Madej
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Minnich
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet M. McComas
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrinia Crouch
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph W. Polli
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew D. Weber
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Overview of human VD,ss prediction methods and input parameters (in silico and in vitro data) evaluated in this study.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Summary of model performance of in silico VD,ss prediction methodologies: (A) ATOM in silico set (n = 956 compounds) and (B) ATOM experimental set (n = 254 compounds).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Predicted vs. observed VD,ss using direct ML models: (A) the ML model built was using a smaller data set (287 compounds), and predictions were tested on a large in silico set (956 compounds) and (B) vice versa. Crosslines indicate 2-, 3-, and 10-fold limits.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Predictive performance of mechanistic Kp prediction methods using various combinations of experimental (Exp.) data.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    (A) Scatter plot [colored by ionic state reported in Lombardo et al. (2018)]. (B) Kernel density plot showing correlation between observed and predicted VD,ss for 254 compounds using experimental (exp) fup and BPR data as input parameters. Crosslines indicate 2-, 3-, and 10-fold limits.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Predictive performance using adipocyte (Kp fat) and myocyte (Kp muscle) partitioning experimental (exp) data.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Comparison of mechanistic tissue partitioning (Kp) prediction methods

    MechanismsPoulin HomogeneousBerezhkovskiyRogers and RowlandLukacovaTrapp Intracellular
    Albumin bindingYesYesYesYesNo
    Neutral phospholipid bindingYesYesYesYesNo
    Neutral lipid bindingYesYesYesYesNo
    Acidic phospholipid bindingNoNoYesYesNo
    Cytosolic ion partitioningNoNoYesYesYes
    Lysosomal ion trappingNoNoNoNoYes
    Mitochondria ion partitioningNoNoNoNoYes
    Membrane potentialNoNoNoNoYes
    Intracellular waterYesYesYesYesYes
    Extracellular waterYesYesYesYesNo
    Tissue-specific compositionYesYesYesYesNo
    • View popup
    TABLE 2

    Summary of model performance of in silico VD,ss prediction methodologies for Lombardo intravenous dosing drug set (n = 1352 drugs) divided into two subsets: 1) ATOM in silico set (>940 compounds) and 2) ATOM experimental set (n > 280 compounds)

    Method DescriptionInput ParametersnWithin 2-FoldWithin 3-FoldWithin 10-Foldr2AAFE
    %
    ADMET mechanisticLog D, fup, BPR (predicted using ADMET Predictor models)9564765900.252.8
    2875171920.352.4
    ATOM mechanisticLog D, fup, BPR (predicted using ATOM ML models)9364562870.233.1
    2855066920.382.7
    Allometry (rat and dog)Rat VD,ss, dog VD,ss (predicted using ATOM ML models)9564566930.282.7
    2834569960.372.5
    Allometry (rat)Rat VD,ss, rat fup, fup (human) (predicted using ATOM ML models)9563047790.024.4
    2832340760.04.9
    Allometry (dog)Dog VD,ss, dog fup, fup (human) (predicted using ATOM ML models)9562843750.054.9
    2832338770.124.7
    Direct ML model for human VD,ssSMILES/MOE descriptors9563655880.143.3
    2855875980.522.2
    • View popup
    TABLE 3

    Summary of mechanistic VD,ss predictive performance using experimental data (fup, BPR, and log D) as input parameters

    Method DescriptionInput ParametersnWithin 2-FoldWithin 3-FoldWithin 10-Foldr2AAFE
    %
    Experimental fupExperimental fup. Other input parameters were predicted by ATOM ML models2545673930.422.3
    Experimental BPRExperimental BPR. Other input parameters were predicted by ATOM ML models2545779960.512.1
    Experimental log DExperimental log D. Other input parameters were predicted by ATOM ML models2544770890.292.7
    Experimental fup, BPRExperimental fup and BPR. Other input parameters were predicted by ATOM ML models2546581960.582.0
    Experimental fup, BPR, log DExperimental fup, BPR, and log D2545976930.462.2
    Experimental fup (BPR = 1)Experimental fup, and BPR is assumed equal to 1. Other input parameters were predicted by ATOM ML models2546376940.482.1
    • View popup
    TABLE 4

    Performance of VD,ss prediction methods utilizing adipocyte and myocyte Kp experimental data

    Method DescriptionInput ParametersnWithin 2-FoldWithin 3-FoldWithin 10-Foldr2AAFE
    %
    Kp fat onlyKp adipocyte, fup and BPR1895468970.422.4
    Kp muscle onlyKp myocyte, fup and BPR1894165940.432.6
    Kp fat and muscleKp adipocyte, Kp myocyte, fup and BPR1893663920.462.9
    Kp average of fat and muscleKp adipocyte, Kp myocyte, fup and BPR1893146830.463.9
    Kp fat and Kp muscle with mechanistic predicted Kp values for other tissuesKp adipocyte, Kp myocyte, fup and BPR, predicted Kp values using ATOM mechanistic models for tissues other than fat and muscle1893356930.483.1
    Kp fat and Kp muscle with mechanistic predicted Kp values for other tissues using experimental log DKp adipocyte, Kp myocyte, fup and BPR, predicted Kp values using ATOM mechanistic models for tissues other than fat and muscle1692746850.413.9
    Lukacova with experimental fup, BPRExperimental fup and BPR. Other input parameters were predicted by ATOM ML models1896076950.502.2

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Data -

      Supplemental Table S1 - Machine learning (ML) models used to predict input parameters for various in silico VD,ss prediction methodologies 

      Supplemental Table S2 - Experimental measurement of physicochemical properties and observed VD,ss values (Lombardo et al., 2018) for 254 compounds

      Supplemental Table S3 - Experimental determination of adipocyte and myocyte cell partitioning of 189 clinical compounds (Lombardo et al., 2018).

      Supplemental Figure S1 - UMAP projection of datasets (a) ATOM in silico and (b)experimental set based on ECFP Tanimoto distances. 

      Supplemental Figure S2 - Scatter/KDE plots of observed versus predicted using various silico VD,ss prediction methodologies listed in Table 2 (a) ATOM in silico set (>940 compounds) and (b) ATOM experimental set (n>280 compounds). Crosslines indicate 2, 3 and 10-fold limits. 

      Supplemental Figure S3 - Measured ChromLogD compared to predicted LogD values by (a) ADMET Predictor (b) ATOM ML model. 

      Supplemental Figure S4 - Scatter/KDE plots of mechanistic VD,ss predictions using various combinations of experimental data (fup, BPR and LogD) as input parameters. 

      Supplemental Figure S5 - Scatter/KDE plots of mechanistic VD,ss predictions using various combinations of experimental data (Kp fat and Kp muscle) as input parameters. 

      Supplemental Figure S6 - Scatter plot of mechanistic VD,ss predictions color coded by ionization using various combinations of experimental data (fup, BPR and LogD) as input parameters.

      Supplemental Figure S7 - Scatter plots of predicted in silico vs observed VD,ss using (a) Allometry (Rat and Dog) and (b) ADMET Mechanistic models. Crosslines indicate 2, 3 and 10-fold limits.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 49 (2)
Drug Metabolism and Disposition
Vol. 49, Issue 2
1 Feb 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Silico Prediction of Volume of Distribution in Humans

Neha Murad, Kishore K. Pasikanti, Benjamin D. Madej, Amanda Minnich, Juliet M. McComas, Sabrinia Crouch, Joseph W. Polli and Andrew D. Weber
Drug Metabolism and Disposition February 1, 2021, 49 (2) 169-178; DOI: https://doi.org/10.1124/dmd.120.000202

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

In Silico Prediction of Volume of Distribution in Humans

Neha Murad, Kishore K. Pasikanti, Benjamin D. Madej, Amanda Minnich, Juliet M. McComas, Sabrinia Crouch, Joseph W. Polli and Andrew D. Weber
Drug Metabolism and Disposition February 1, 2021, 49 (2) 169-178; DOI: https://doi.org/10.1124/dmd.120.000202
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Retroconversion of PQ and Its N-Oxide Metabolites
  • Deoxycholate Oxidation Is Predictive of CYP3A Activity
  • REF vs RAF Prediction of Renal Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics